Risk for deaths from natural causes, unnatural causes significantly increased for persons with autism spectrum disorder
MONDAY, Feb. 14, 2022 (HealthDay News) — The risk for mortality is increased significantly for persons with autism spectrum disorders (ASD) and those with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published online Feb. 14 in JAMA Pediatrics.
Ferrán Catalá-López, Ph.D., from the Ottawa Hospital Research Institute in Ontario, Canada, and colleagues, conducted a systematic review to examine the risk for mortality among persons with ASD or ADHD and their first-degree relatives. Data were included from 27 studies, with 642,260 individuals.
The researchers found that all-cause mortality was increased for persons with ASD and for those with ADHD (rate ratios, 2.37 [95 percent confidence interval, 1.97 to 2.85] and 2.13 [95 percent confidence interval, 1.13 to 4.02], respectively) compared with the general population. Increased deaths from natural causes and from unnatural causes were seen among persons with ASD (rate ratios, 3.80 [95 percent confidence interval, 2.06 to 7.01] and 2.50 [95 percent confidence interval, 1.49 to 4.18], respectively). No significant increase was seen for deaths from natural causes (rate ratio, 1.62; 95 percent confidence interval, 0.89 to 2.96), but deaths from unnatural causes were significantly higher than expected among persons with ADHD (rate ratio, 2.81; 95 percent confidence interval, 1.73 to 4.55).
“Understanding the mechanisms of these associations may lead to targeted strategies to prevent avoidable deaths in high-risk groups of children and young people as an approach to improve public health,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
People With ADHD Experience 50 Percent More GI Symptoms
People With Autism Have Shorter Life Expectancy
Autism Spectrum Disorder Diagnoses Increased for Females Since 2020
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus